In the past decade, several molecular-targeted agents, such as epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), have emerged and are currently used in the treatment of advanced non-small cell lung cancer (NSCLC). This evidence concerns the gene EGFR and non-small cell lung carcinoma.